

## Special Issue

# Pharmacoepidemiology in Vaccine: Generating the Real-World Data to Promote Vaccine Safety and Uptake

### Message from the Guest Editors

We are currently living in a post-vaccine era where historically known communicable and life-threatening infectious diseases are in under control by an effective immunization strategy. Researchers are utilizing post-marketing surveillance data to generate real-world data to promote vaccine safety. This special issue titled as “Pharmacoepidemiology in vaccine: Generating the real-world data to promote vaccine safety and uptake” will introduce the readers of the Journal a pharmacoepidemiologic approach to address vaccine safety and hesitancy. Specifically, this issue encompasses the following areas of research: (1) identifying unsuspected AEFIs by applying novel statistical methods in post-marketing surveillance data; (2) conducting observational study for casual inference on the safety of vaccine(s); (3) describing interventions or strategies to combat vaccine hesitancy. Manuscripts that address any of these research areas are welcome for submission.

### Guest Editors

Prof. Ju-Young Shin

Department of Clinical and Social Pharmacy, School of Pharmacy, Sungkyunkwan University (SKKU), Suwon 16419, Korea

Dr. Ju Hwan Kim

School of Pharmacy, Sungkyunkwan University (SKKU), Suwon 16419, Korea

### Deadline for manuscript submissions

closed (30 May 2021)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/58341](https://mdpi.com/si/58341)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).